Targets › PLMN
1 program from 1 company in 3 trials: 3 Phase 3; Neurology, Cardiovascular; next expected readout Jun 2028.
Open in Phaseline: the race on PLMN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Supergene | Non-immunogenic recombinant staphylokinase (Fortelyzin®) Staphylokinase, a plasminogen activator | PLG, PLMN | Phase 3 | Acute Limb Ischemia; Pulmonary Embolism; Ischemic Stroke, Acute | Jun 2028 |
Acute Limb Ischemia (1) Pulmonary Embolism (1) Ischemic Stroke, Acute (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.